The Tumor Immune Microenvironment plays a Key Role in Driving the Progression of Cholangiocarcinoma

Author:

Zhang Ye1,Yan Hai-jiao1,Wu Jun1

Affiliation:

1. Department of Oncology, The Third Affiliated Hospital of Soochow University, 185 Juqian St, Changzhou, 213003, China

Abstract

Abstract: Cholangiocarcinoma (CCA) is an epithelial cancer distinguished by bile duct cell differentiation and is also a fibroproliferative tumor. It is characterized by a dense mesenchyme and a complex tumor immune microenvironment (TME). The TME comprises both cellular and non-cellular components. The celluar component includes CCA cells, immune cells and mesenchymal cells represented by the cancer-associated fibroblasts (CAFs), while the non-cellular component is represented by mesenchymal elements such as the extracellular matrix (ECM). Recent studies have demonstrated the important role of the TME in the development, progression, and treatment resistance of CCA. These cell-associated prognostic markers as well as intercellular connections, may serve as potential therapeutic targets and could inspire new treatment approaches for CCA in the future. This paper aims to summarize the current understanding of CCA's immune microenvironment, focusing on immune cells, mesenchymal cells, ECM, intercellular interactions, and metabolism within the microenvironment.

Funder

Key Program of the Changzhou Commission of Health

Major science and technology project of Changzhou Municipal Health Commission

Publisher

Bentham Science Publishers Ltd.

Reference121 articles.

1. Banales J.M.; Marin J.J.G.; Lamarca A.; Rodrigues P.M.; Khan S.A.; Roberts L.R.; Cardinale V.; Carpino G.; Andersen J.B.; Braconi C.; Calvisi D.F.; Perugorria M.J.; Fabris L.; Boulter L.; Macias R.I.R.; Gaudio E.; Alvaro D.; Gradilone S.A.; Strazzabosco M.; Marzioni M.; Coulouarn C.; Fouassier L.; Raggi C.; Invernizzi P.; Mertens J.C.; Moncsek A.; Rizvi S.; Heimbach J.; Koerkamp B.G.; Bruix J.; Forner A.; Bridgewater J.; Valle J.W.; Gores G.J.; Cholangiocarcinoma 2020: The next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol 2020,17(9),557-588

2. Rimassa L.; Personeni N.; Aghemo A.; Lleo A.; The immune milieu of cholangiocarcinoma: From molecular pathogenesis to precision medicine. J Autoimmun 2019,100,17-26

3. Nakamura H.; Arai Y.; Totoki Y.; Shirota T.; Elzawahry A.; Kato M.; Hama N.; Hosoda F.; Urushidate T.; Ohashi S.; Hiraoka N.; Ojima H.; Shimada K.; Okusaka T.; Kosuge T.; Miyagawa S.; Shibata T.; Genomic spectra of biliary tract cancer. Nat Genet 2015,47(9),1003-1010

4. Xia T.; Li K.; Niu N.; Shao Y.; Ding D.; Thomas D.L.; Jing H.; Fujiwara K.; Hu H.; Osipov A.; Yuan C.; Wolfgang C.L.; Thompson E.D.; Anders R.A.; He J.; Mou Y.; Murphy A.G.; Zheng L.; Immune cell atlas of cholangiocarcinomas reveals distinct tumor microenvironments and associated prognoses. J Hematol Oncol 2022,15(1),37

5. Montal R.; Sia D.; Montironi C.; Leow W.Q.; Esteban-Fabró R.; Pinyol R.; Torres-Martin M.; Bassaganyas L.; Moeini A.; Peix J.; Cabellos L.; Maeda M.; Villacorta-Martin C.; Tabrizian P.; Rodriguez-Carunchio L.; Castellano G.; Sempoux C.; Minguez B.; Pawlik T.M.; Labgaa I.; Roberts L.R.; Sole M.; Fiel M.I.; Thung S.; Fuster J.; Roayaie S.; Villanueva A.; Schwartz M.; Llovet J.M.; Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma. J Hepatol 2020,73(2),315-327

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3